Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Endocyte Drug Slows Lung Cancer Progression

March 21, 2014 2:55 pm | News | Comments

Endocyte Inc. announced results from a Phase 2b trial, which showed that the study met the primary endpoint for the combination of vintafolide and docetaxel in folate receptor-positive recurrent non-small cell lung cancer patients. Read more...  


Committee OKs Expanded Use of Novo Nordisk Drugs

March 21, 2014 2:44 pm | News | Comments

The Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for expanded use of Tresiba (insulin degludec) and Victoza (liraglutide) in type 2 diabetes. Read more...                  


Substance Makes Glioblastoma Cells Explode

March 21, 2014 2:39 pm | News | Comments

Researchers have discovered that a substance called Vacquinol-1 makes cells from glioblastoma, the most aggressive type of brain tumor, literally explode. When mice were given the substance, tumor growth was reversed and survival was prolonged. Read more...


Investigational Drug Evaluated in Newborns with Rare Disorder

March 21, 2014 2:31 pm | News | Comments

Children with a rare genetic disorder that causes missing and malformed teeth, sparse hair and the inability to perspire are born without a key developmental protein. A clinical trial now underway aims to see if the void can be filled with replacement-protein therapy. Read more...


Novartis Starting New Head-to-Head Psoriasis Trial

March 21, 2014 2:10 pm | News | Comments

Novartis announced that a new Phase 3b head-to-head study of IL-17A inhibitor secukinumab (AIN457) versus Stelara (ustekinumab) in moderate-to-severe plaque psoriasis has started patient enrollment. Read more..           


Simeprevir for Hep C Closer to EU Approval

March 21, 2014 11:19 am | News | Comments

Medivir AB announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending Marketing Authorization in the European Union for the use of simeprevir. in combination with other drugs, for the treatment of chronic hepatitis C. Read more...


Takeda's UC, Crohn's Drug Gets OK from EU Committee

March 21, 2014 11:08 am | News | Comments

Takeda announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion for Entyvio (vedolizumab) for the treatment of adults with ulcerative colitis (UC) and Crohn's disease (CD). Read more...


Oral Chemotherapy Trial Launched in New Zealand

March 21, 2014 11:00 am | News | Comments

Kinex Pharmaceuticals announced that the company has received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand. Read more...        


CHMP Recommends EU Approval of Empagliflozin for Diabetes

March 21, 2014 10:41 am | News | Comments

Boehringer Ingelheim and Eli Lilly and Co. announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin in adults with type 2 diabetes. Read more...


UK Panel Backs Bexsero for National Immunization Program

March 21, 2014 10:24 am | News | Comments

Novartis announced that the Joint Committee on Vaccination and Immunization in the UK has recommended the inclusion of Bexsero (Meningococcal Group B Vaccine) in the National Immunization Program. Read more...           


Canada Gives First Approval of Biogen Hemophilia Drug

March 21, 2014 10:04 am | News | Comments

Biogen Idec announced that Health Canada has approved Alprolix for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. Read more...           


Janssen Halts Schizophrenia Drug Trial on Positive Efficacy

March 20, 2014 3:10 pm | News | Comments

Janssen Research & Development announced that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of an investigational schizophrenia treatment. Read more...


FDA Names Pfizer MenB Vaccine as Breakthrough Therapy

March 20, 2014 3:02 pm | News | Comments

Pfizer announced that the FDA has granted Breakthrough Therapy designation to Pfizer’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B. Read more...


Hawaii Sues BMS, Sanofi Over Plavix

March 20, 2014 2:43 pm | by Jennifer Sinco Kelleher | News | Comments

Hawaii's attorney general is suing the makers of a widely prescribed blood thinner that he says a significant portion of the state's population has difficulty metabolizing. The suit names Bristol-Myers Squibb and Sanofi-Aventis as defendants. Read more...


Agenus-GSK Lung Cancer Drug Disappoints in Trial

March 20, 2014 2:18 pm | News | Comments

Shares of Agenus tumbled more than 13% Thursday before markets opened and after the biopharmaceutical released more ineffective study results from its collaboration with GlaxoSmithKline. Read more...               



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.